Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems
Executive Summary
Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.
You may also be interested in...
Schering-Plough To Pay $165 Million To Shareholders For Clarinex Delay
The company is settling claims it failed to reveal that negative FDA inspection reports would delay approval of its allergy medicine.
Schering Clarinex Approval Comes In Time For Big Spring Push
Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season
Schering Clarinex Approval Comes In Time For Big Spring Push
Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season